JP2002517448A - 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用 - Google Patents

精神障害の治療用ｎｋ−１受容体アンタゴニストの使用

Info

Publication number
JP2002517448A
JP2002517448A JP2000553079A JP2000553079A JP2002517448A JP 2002517448 A JP2002517448 A JP 2002517448A JP 2000553079 A JP2000553079 A JP 2000553079A JP 2000553079 A JP2000553079 A JP 2000553079A JP 2002517448 A JP2002517448 A JP 2002517448A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
hydroxyethoxy
methylmorpholine
fluorophenyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000553079A
Other languages
English (en)
Japanese (ja)
Inventor
ルプニアツク，ナデイア・メラニー
Original Assignee
メルク シャープ エンド ドーム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812661.8A external-priority patent/GB9812661D0/en
Priority claimed from GBGB9812669.1A external-priority patent/GB9812669D0/en
Priority claimed from GBGB9812663.4A external-priority patent/GB9812663D0/en
Application filed by メルク シャープ エンド ドーム リミテッド filed Critical メルク シャープ エンド ドーム リミテッド
Publication of JP2002517448A publication Critical patent/JP2002517448A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000553079A 1998-06-11 1999-06-08 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用 Withdrawn JP2002517448A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9812663.4 1998-06-11
GB9812669.1 1998-06-11
GBGB9812661.8A GB9812661D0 (en) 1998-06-11 1998-06-11 Therapeutic use
GBGB9812669.1A GB9812669D0 (en) 1998-06-11 1998-06-11 Therapeutic use
GBGB9812663.4A GB9812663D0 (en) 1998-06-11 1998-06-11 Therapeutic use
GB9812661.8 1998-06-11
PCT/GB1999/001819 WO1999064010A1 (fr) 1998-06-11 1999-06-08 Utilisation d'un antagoniste du recepteur nk-1 dans le traitement des troubles psychiatriques

Publications (1)

Publication Number Publication Date
JP2002517448A true JP2002517448A (ja) 2002-06-18

Family

ID=27269359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000553079A Withdrawn JP2002517448A (ja) 1998-06-11 1999-06-08 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用

Country Status (5)

Country Link
EP (1) EP1085875A1 (fr)
JP (1) JP2002517448A (fr)
AU (1) AU4279699A (fr)
CA (1) CA2334609A1 (fr)
WO (1) WO1999064010A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043532A1 (fr) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. Agent thérapeutique pour la maladie de parkinson
JP2008509103A (ja) * 2004-08-06 2008-03-27 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症に対するｎｋ１／ｎｋ３二重アンタゴニスト

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
DE10111058A1 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten
US6620438B2 (en) 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
WO2009109001A1 (fr) * 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Procédé de prévention et/ou de traitement d’une maladie, d’une condition ou d’un état associés à une fonction réduite des neurones dopaminergiques

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL181214B1 (pl) * 1993-12-29 2001-06-29 Merck Sharp & Dohme Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
GB9523244D0 (en) * 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
DE69732133T2 (de) * 1996-12-02 2005-12-22 Merck Sharp & Dohme Ltd., Hoddesdon Verwendung von NK-1 Rezeptorantagonisten zur Behandlung von schweren Depressionen
AU729708B2 (en) * 1996-12-02 2001-02-08 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating severe anxiety disorders
CA2273800A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des etats depressifs majeurs accompagnes d'anxiete
ATE274908T1 (de) * 1996-12-02 2004-09-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen
CA2273856A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles bipolaires
WO1998024444A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles du sevrage
CA2273807A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles schizophreniques

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509103A (ja) * 2004-08-06 2008-03-27 エフ．ホフマン−ラ ロシュ アーゲー 統合失調症に対するｎｋ１／ｎｋ３二重アンタゴニスト
WO2006043532A1 (fr) * 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. Agent thérapeutique pour la maladie de parkinson

Also Published As

Publication number Publication date
WO1999064010A1 (fr) 1999-12-16
EP1085875A1 (fr) 2001-03-28
AU4279699A (en) 1999-12-30
CA2334609A1 (fr) 1999-12-16

Similar Documents

Publication Publication Date Title
JP2002532393A (ja) エキソ−ｒ−メカミラミン製剤および治療におけるその使用
EP1904182A2 (fr) Methode de traitement de la toxicomanie avec flibanserine
CZ290115B6 (cs) Farmaceutický prostředek
EP0278161B1 (fr) Dérivés de cétone comme médicaments pour le traitement ou la prévention du syndrome associé à un état de manque
JP2001502311A (ja) 抗鬱及び／又は抗不安薬としてのｃｎｓ浸透性ｎｋ―１受容体拮抗薬
US5180729A (en) Use of sigma receptor antagonists for treatment of cocaine abuse
US5629336A (en) Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal
JP2002517448A (ja) 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用
CA2357901A1 (fr) Traitement combine contre la depression et l'anxiete
ES2231901T3 (es) Uso de antagonistas del receptor de nk-1 para tratar transtornos por el uso de sustancias.
US20220184072A1 (en) Methods of treating neuropathic pain
WO2001078729A1 (fr) Procede d'inhibition de dopamine utilisant du l-threo-methylphenidate
JP2001507678A (ja) 運動障害の治療のためのｎｋ−１受容体拮抗薬の使用
CA2455585A1 (fr) Composes pour le traitement de l'anhedonie
ES2227728T3 (es) Uso de antagonistas del receptor de nk-1 para tratar trastornos de ests.
JP2002517446A (ja) 精神障害の治療のためのｎｋ−１受容体アンタゴニストの使用
JP2001504850A (ja) 不安を伴う重抑鬱性障害を治療するためのｎｋ−１受容体拮抗薬の使用
JP2001511159A (ja) オキシムを含むシナプス機能障害の処置用医薬組成物
US11596622B2 (en) Mazindol treatment for heroin dependence and substance use disorder
JP2023510082A (ja) 認知症患者における行動・心理症状を治療するための方法
JP2002517447A (ja) 双極性障害の治療のためのｎｋ−１受容体アンタゴニストの使用
KR20080034475A (ko) 수면제 및ｒ(＋)-알파-(2,3-디메톡시-페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 복합물 및 이의 치료학적 용도
JPH1160482A (ja) 性機能改善剤
CA2334607A1 (fr) Utilisation d'un antagoniste du recepteur nk-1 pour le traitement de dysfonctionnements sexuels

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060905